MedTrace Logo

Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia

NCT02337660 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-11-16

No results posted yet for this study

Summary

The purpose of this study is to examine whether non-alcoholic fatty liver disease (NAFLD) is associated with hepatic glucagon resistance and hyperglucagonemia.

Conditions

  • Non-alcoholic Fatty Liver Disease

Interventions

PROCEDURE

Liver biopsy

One ultrasound guided liver biopsy

OTHER

Pancreatic clamp

I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.

Sponsors & Collaborators

  • The Novo Nordisk Foundation Center for Basic Metabolic Research

    collaborator OTHER

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-01-31
Completion
2016-01-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02337660 on ClinicalTrials.gov